drugset / Trial / NCT07159841

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

NCT07159841

Phase 2/3 Recruiting 153 enrolled Crinetics Pharmaceuticals Inc.
RandomizedSequentialTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).

Timeline

Start
2026-01-22
Primary completion
2030-03
Completion
2030-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Atumelnant Small molecule Oral